thromboplastin and Thalassemia

Patients with thalassemia exhibit an increased risk of thrombotic events that is augmented after splenectomy. Heparanase protein enhances cancer progression, angiogenesis, and inflammation; it also activates the coagulation system through direct interaction with tissue factor (TF). Additionally, erythropoietin, which is elevated in anemic patients, up-regulates heparanase expression via the Janus kinase 2 (JAK-2) pathway. This study aimed was to explore the heparanase profile in thalassemia. Coagulation factors were analyzed via immunostaining, enzyme-linked immunosorbent assay, and heparanase procoagulant activity assay. In spleen specimens of thalassemia major patients, a higher level of heparanase staining was observed compared with control spleens resected after trauma (P < 0.001). Higher heparanase levels, heparanase and TF procoagulant activity, and erythropoietin levels were found in the plasma of 67 thalassemia major patients compared with 29 control subjects. No difference was found in pediatric patients (23 of 67) compared with adults or splenectomized versus nonsplenectomized patients. Higher levels of heparanase, TF, TF pathway inhibitor, and TF pathway inhibitor-2 were observed in liver, spleen, heart, and kidney tissues of thalassemia intermedia mice (Hbb

Topics: Adult; Animals; Blood Coagulation; Glucuronidase; Humans; Janus Kinase 2; Lipoproteins; Male; Mice, Inbred C57BL; Thalassemia; Thromboplastin; Thrombosis; Young Adult

To explore whether the high risk factors possibly leading to hypercoagulative status and thrombosis exist in Thalassemia patients of Guangxi region through detecting plasma tissne factor-bearing microparticles (TF. The TF. Compared with control group, the AT-Ⅲ level decreased in β-thalastemia major group (TM) (P<0.05), the AT-Ⅲ level in TM group independeutly posstiody correlated with plt count (r=0.37, P<0.05); the levels of TF and sICAM in α-thalassenia intermediate group (TA) significantly decteased (P<0.05), the procoagulatim activity of TF. The damage of liver function and reduction of anticoagylation substances exist in patients with β-thalassenia major in Guangxi region, the procoagulation activity of plasma TF. 地中海贫血患者组织因子微粒促凝活性及抗凝血酶Ⅲ检测的意义.. 通过检测地中海贫血患者血浆组织因子微粒（TF. 对71例地中海贫血组及20例正常对照组分别用发色底物法检测血浆TF. 广西重型β地中海贫血患者有肝功能损害及抗凝物质的减少;中间型β自中海贫血患者血浆TF

Topics: Anticoagulants; Antithrombin III; China; Humans; Thalassemia; Thromboplastin; Tissue Plasminogen Activator

To investigate the changes of E-selectin, thrombin-antithrombin complex（TAT）, prothrombin fragment 1+2（F1+2）, tissue factor（TF）and tissue factor pathway inhibitor（TFPI）before and one year after splenectomy in thalassemia patients.. A total of 30 thalassemia patients undergoing electric laparoscopic splenectomy and 30 normal controls（NC） were enrolled in the study．Plasma levels of E-selectin, TAT, F1+2, TF and TFPI were detected by enzyme-linked immuno sorbent assay（ELISA）.. One year after splenectomy，the plasma concentrations of E-selectin, TAT, F1+2, TF, TFPI were significantly higher than those in both preoperative and NC groups．Levels of E-selectin, TAT, F1+2 before splenectomy were significantly higher than those in NC groups. In addition, there was a positive correlation between plasma TF and TFPI level before and after splenectomy, and the levels of TF and TFPI positively correlated with TAT and F1+2, respectively.. After splenectomy, the platelet count increases, the activity of endothelial cells is injured, the procoagulant factor increases, the blood is in procoagulant state, the TF/TFPI shows an importent role in the thrombosis of thalassemia patieints after splenectomy and may be used to evaluate the prothrombotic state of this diasease.

Topics: Blood Coagulation; Humans; Lipoproteins; Thalassemia; Thromboplastin

Topics: Humans; Lipoproteins; Splenectomy; Thalassemia; Thromboplastin

A syndrome of intracranial hemorrhage with gross prolongation of the prothrombin and partial thromboplastin times, with normal thrombin time, fibrinogen concentrations, and coagulation factor assays is described in four children with homozygous beta-thalassemia. Mixing experiments and plasma thromboplastin inhibition tests revealed a persistent abnormality which was consistent with the presence of a circulatory prothrombinase inhibitor. The origin of this previously unreported inhibitor in thalassemia remains speculative.

Topics: Cerebral Hemorrhage; Child; Female; Humans; Immunoglobulin M; Male; Partial Thromboplastin Time; Prothrombin Time; Thalassemia; Thromboplastin

Topics: Female; Hemoglobins; Humans; Male; Thalassemia; Thromboplastin

Topics: Blood Coagulation Disorders; Glutathione; Humans; Thalassemia; Thromboplastin

Topics: Adolescent; Adult; Blood Coagulation Disorders; Child; Hemoglobins, Abnormal; Humans; In Vitro Techniques; Thalassemia; Thromboplastin